Quantum Leap Health Carecollaborative
- Assets
- $58.2m
- Revenue
- $45.1m
- Investments
- $0.0
- Employees
- 121
- Location
- San Francisco, CA
- Founding
- 08/2006
- Data as of
- 12/2023
- EIN
- 20-4284925
Organization Overview
Quantum Leap Health Carecollaborative is located in San Francisco, CA. The organization was established in 2006. According to its NTEE Classification (P20) the organization is classified as: Human Service Organizations, under the broad grouping of Human Services and related organizations. As of 12/2023, Quantum Leap Health Carecollaborative employed 121 individuals. This organization is an independent organization and not affiliated with a larger national or regional group of organizations. Quantum Leap Health Carecollaborative is a 501(c)(3) and as such, is described as a "Charitable or Religous organization or a private foundation" by the IRS.
For the year ending 12/2023, Quantum Leap Health Carecollaborative generated $45.1m in total revenue. This organization has experienced exceptional growth, as over the past 8 years, it has increased revenue by an average of 18.7% each year . All expenses for the organization totaled $47.8m during the year ending 12/2023. While expenses have increased by 24.5% per year over the past 8 years. They've been increasing with an increasing level of total revenue. You can explore the organizations financials more deeply in the financial statements section below.
Form
990
Mission & Program ActivityExcerpts From the 990 Filing
TAX YEAR
2023
Describe the Organization's Mission:
Part 3 - Line 1
THE MISSION OF QUANTUM LEAP HEALTHCARE COLLARBORATIVE IS TO PROVIDE (CONTINUED ON SCH. O)MANAGEMENT AND FINANCIAL SUPPORT TO HEALTHCARE RESEARCH ORGANIZATIONS, PARTICULARLY INVOLVING BREAST CANCER RESEARCH AND TREATMENT.
Describe the Organization's Program Activity:
Part 3 - Line 4a
I-SPY TRIALS: QUANTUM LEAP SPONSORS THE I-SPY TRIALS (INVESTIGATION OF SERIAL STUDIES TO PREDICT YOUR THERAPEUTIC RESPONSE WITH IMAGING AND MOLECULAR ANALYSIS). I-SPY HAS BEEN RE-ENGINEERING THE APPROACH TO CLINICAL TRIALS, WITH A GOAL OF GETTING THE RIGHT DRUG TO THE RIGHT PATIENT AT THE TIME WHEN THEY WILL BENEFIT MOST, AND TO ACHIEVE THIS FASTER THAN POSSIBLE IN PREVIOUS TRIAL MODELS. ADDITIONALLY, I-SPY AIMS TO SIGNIFICANTLY REDUCE THE OVERALL COST, TIME, AND NUMBER OF PATIENTS REQUIRED TO BRING NEW DRUGS TO MARKET. THE I-SPY TRIAL PROGRAM INTEGRATES AND LINKS PHASE I (I-SPY PHASE 1), PHASE II (I-SPY 2), AND FUTURE PHASES TO BUILD A PIPELINE OF NOVEL AGENTS AND ACCELERATE THE PROCESS OF IDENTIFYING THE SUBSET OF HIGH-RISK BREAST CANCER PATIENTS THAT WILL BENEFIT FROM THESE NEW AGENTS, AND GET THESE DRUG INTO THE CLINIC IN A TIMELY MANNER.
THE COVID/ARDS STUDY TRIAL FOCUSED ON PATIENTS WHOSE REACTIONS TO THE VIRUS MAKE THEM CRITICALLY ILL AND, IN MANY CASES, RESULT IN DEATH. THE TRIAL'S PRIMARY FOCUS WAS TO IDENTIFY PROMISING DRUGS THAT EITHER NEUTRALIZE THE VIRUS, HELP HEAL THE LUNG DAMAGE FROM THE VIRUS (WHICH CAUSED ACUTE RESPIRATORY DISTRESS SYNDROME), OR CHANGE THE IMMUNE SYSTEM REACTION RESULTING IN ILLNESS. THE TRIAL OPENED IN JUNE 2020 AND WILL CONTINUE UNTIL A DRUG OR COMBINATIONS OF DRUGS ARE FOUND THAT PREVENT THE NECESSITY FOR VENTILATION TREATMENT AND ELIMINATE DEATH FROM THE DISEASE. IN FISCAL YEAR 2022, THE PROTOCOL WAS AMENDED TO EXPAND TO ALL ILLNESSES CONTRIBUTING TO ADULT RESPIRATORY DISTRESS SYNDROME, OR ARDS.
BREAST CANCER TRIALS (BCT) - LAUNCHED IN 2008, FOLLOWING A SUCCESSFUL UCSF-NCI SPONSORED RESEARCH PILOT, ITS MISSION IS TO MAKE PATIENT CONSIDERATION OF TRIALS THE NORM VS. THE EXCEPTION. WE BELIEVE THAT ALL PATIENTS SHOULD HAVE ACCESS TO THE LATEST MEDICAL KNOWLEDGE ABOUT BREAST CANCER TREATMENT AS WELL AS THE OPPORTUNITY TO ADVANCE BREAST CANCER RESEARCH. BCT LISTS OVER 600 STUDIES FOR PEOPLE WITH NEWLY DIAGNOSED BREAST CANCER, METASTATIC DISEASE, OR POST-TREATMENT SURVIVORS. IT INCLUDES INNOVATIVE TRIALS OF TARGETED AND IMMUNOTHERAPIES AS WELL AS OBSERVATIONAL STUDIES LOOKING AT QUALITY OF LIFE, GENETIC MUTATIONS, AND BREAST CANCER SURVIVORSHIP, ACCOMPANIED BY EASY-TO-READ TRIAL SUMMARIES.
Get More from Intellispect for FreeCreate a free account to get more data, nonprofit salaries, advanced search and more.
Board, Officers & Key Employees
| Name (title) | Role | Hours | Compensation |
|---|---|---|---|
Dave Mandelkern Ms Chairman | OfficerTrustee | 8 | $120,000 |
Laura Esserman Director, Cofounder | Trustee | 0.5 | $0 |
Jeffery Pfeffer PHD Director, Cofounder | Trustee | 0.5 | $0 |
Anna Barker PHD Director | Trustee | 0.5 | $0 |
Lucas DE Breed PHD MBA Director | Trustee | 0.5 | $0 |
Susan Foley CFA Director | Trustee | 0.5 | $0 |
Outside Vendors & Contractors
| Vendor Name (Service) | Service Year | Compensation |
|---|---|---|
Regents Of Uc San Francisco Clinical Research | 12/30/23 | $7,612,315 |
University Of Alabama At Birmingham - Co Clinical Research | 12/30/23 | $2,400,175 |
Regents Of The University Of Minnesota Clinical Research | 12/30/23 | $1,234,991 |
University Of California San Diego Clinical Research | 12/30/23 | $2,189,647 |
Wake Forest University Health Sciences Clinical Research | 12/30/23 | $1,014,700 |
Financial Statements
| Statement of Revenue | |
|---|---|
| Federated campaigns | $0 |
| Membership dues | $0 |
| Fundraising events | $0 |
| Related organizations | $0 |
| Government grants | $0 |
| All other contributions, gifts, grants, and similar amounts not included above | $1,389,552 |
| Noncash contributions included in lines 1a–1f | $645,302 |
| Total Revenue from Contributions, Gifts, Grants & Similar | $1,389,552 |
| Total Program Service Revenue | $42,063,571 |
| Investment income | $1,587,428 |
| Tax Exempt Bond Proceeds | $0 |
| Royalties | $0 |
| Net Rental Income | $0 |
| Net Gain/Loss on Asset Sales | $107,348 |
| Net Income from Fundraising Events | $0 |
| Net Income from Gaming Activities | $0 |
| Net Income from Sales of Inventory | $0 |
| Miscellaneous Revenue | $0 |
| Total Revenue | $45,147,899 |
| Statement of Expenses | |
|---|---|
| Grants and other assistance to domestic organizations and domestic governments. | $0 |
| Grants and other assistance to domestic individuals. | $0 |
| Grants and other assistance to Foreign Orgs/Individuals | $0 |
| Benefits paid to or for members | $0 |
| Compensation of current officers, directors, key employees. | $2,040,706 |
| Compensation of current officers, directors, key employees. | $743,937 |
| Compensation to disqualified persons | $0 |
| Other salaries and wages | $13,879,772 |
| Pension plan accruals and contributions | $474,768 |
| Other employee benefits | $2,138,650 |
| Payroll taxes | $1,061,149 |
| Fees for services: Management | $0 |
| Fees for services: Legal | $109,511 |
| Fees for services: Accounting | $268,183 |
| Fees for services: Lobbying | $0 |
| Fees for services: Fundraising | $0 |
| Fees for services: Investment Management | $20,144 |
| Fees for services: Other | $2,190,326 |
| Advertising and promotion | $419,308 |
| Office expenses | $95,009 |
| Information technology | $3,232,348 |
| Royalties | $0 |
| Occupancy | $355,935 |
| Travel | $255,671 |
| Payments of travel or entertainment expenses for any federal, state, or local public officials | $0 |
| Conferences, conventions, and meetings | $173,488 |
| Interest | $11,113 |
| Payments to affiliates | $0 |
| Depreciation, depletion, and amortization | $101,152 |
| Insurance | $86,553 |
| All other expenses | $24,566 |
| Total functional expenses | $47,759,442 |
| Balance Sheet | |
|---|---|
| Cash—non-interest-bearing | $249,898 |
| Savings and temporary cash investments | $5,385,955 |
| Pledges and grants receivable | $279,603 |
| Accounts receivable, net | $8,639,920 |
| Loans from Officers, Directors, or Controlling Persons | $0 |
| Loans from Disqualified Persons | $0 |
| Notes and loans receivable | $0 |
| Inventories for sale or use | $0 |
| Prepaid expenses and deferred charges | $725,047 |
| Net Land, buildings, and equipment | $113,294 |
| Investments—publicly traded securities | $42,672,001 |
| Investments—other securities | $0 |
| Investments—program-related | $0 |
| Intangible assets | $0 |
| Other assets | $136,242 |
| Total assets | $58,201,960 |
| Accounts payable and accrued expenses | $12,880,683 |
| Grants payable | $0 |
| Deferred revenue | $15,030,847 |
| Tax-exempt bond liabilities | $0 |
| Escrow or custodial account liability | $0 |
| Loans and other payables to any current Officer, Director, or Controlling Person | $0 |
| Secured mortgages and notes payable | $0 |
| Unsecured mortgages and notes payable | $0 |
| Other liabilities | $1,463,193 |
| Total liabilities | $29,374,723 |
| Net assets without donor restrictions | $28,638,301 |
| Net assets with donor restrictions | $188,936 |
| Capital stock or trust principal, or current funds | $0 |
| Paid-in or capital surplus, or land, building, or equipment fund | $0 |
| Retained earnings, endowment, accumulated income, or other funds | $0 |
| Total liabilities and net assets/fund balances | $58,201,960 |
Grants Awarded
Over the last fiscal year, Quantum Leap Health Carecollaborative has awarded $297,497 in support to 5 organizations.
| Grant Recipient | Amount |
|---|---|
UNIVERSITY OF ALABAMA AT BIRMINGHAM PURPOSE: TO SUPPORT EXPANSION SITES PARTICIPATING IN THE WISDOM STUDY | $60,000 |
UCSF FOUNDATION PURPOSE: SUPPORT CALM PROGRAM | $72,500 |
UNIVERSITY OF CHICAGO PURPOSE: TO SUPPORT EXPANSION SITES PARTICIPATING IN THE WISDOM STUDY | $29,000 |
UNIVERSITY OF CALIFORNIA IRVINE PURPOSE: TO SUPPORT EXPANSION SITES PARTICIPATING IN THE WISDOM STUDY | $75,997 |
LSU HEALTH SCIENCE CENTER PURPOSE: TO SUPPORT EXPANSION SITES PARTICIPATING IN THE WISDOM STUDY | $60,000 |